Drug Profile
PC 1250
Alternative Names: Bathocuproine disulfonic acid copper; BCDS Cu(I)Latest Information Update: 22 Oct 2003
Price :
$50
*
At a glance
- Originator ProCyte Corporation
- Class Anti-inflammatories; Antivirals; Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Jan 2001 Discontinued - Phase-I for HIV infections treatment in USA (unspecified route)
- 10 Feb 1998 Phase-I clinical trials for HIV infections treatment in USA (Unknown route)
- 23 Aug 1995 Preclinical development for HIV infections treatment in USA (Unknown route)